Literature DB >> 183789

Antilipidemic drugs. Part 6: LF 178 in man. A preliminary note on a multicenter investigation bearing on 393 subjects with pure or mixed forms of hyperlipidemia.

B Wülfert, B Majoie, A de Ceaurriz.   

Abstract

A total of 393 patients affected by different foms of hyperlipoproteinemia have been treated for up to 12 months or more with a daily dose of 200-400 mg of isopropyl-4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl]-propionate (LF 178; procetofene; Lipanthyl). In pure hypercholesterolemia (IIa) the mean depression of cholesterol exceeded 26% and the drug induced degree of normalization was 85%. In mixed hypercholesterolemia (IIa) cholesterol was depressed by 23% and triglycerides by approximately 40%. In major affections of hypercholesterolemia (cholesterol > 3.5 gll) the mean induced depression exceeded 30%. Pure hypertriglyceridemia (IV) was strongly affected by the drug LF 178 induced a mean depression of triglycerides exceeding 60% after 6 months of treatment. In all cases the antilipidemic effect was fast and well sustained...

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 183789

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  3 in total

1.  The influence of renal insufficiency and haemodialysis on the kinetics of ciprofibrate.

Authors:  N Ferry; N Bernard; N Pozet; E Gardes; G Cuisinaud; M Labeeuw; P Y Zech; J Sassard
Journal:  Br J Clin Pharmacol       Date:  1989-12       Impact factor: 4.335

2.  Distribution of fenofibric acid in lipoprotein fractions of patients.

Authors:  M Nobilis; J Kvetina; P Anzenbacher; T Vontor; D Svoboda; M Brátová; D Solichová; Z Zadák; V Bláha; J Vlcek
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Apr-Jun       Impact factor: 2.441

3.  Antiviral activity of antilipidemic compounds on herpes simplex virus type 1.

Authors:  J K Mehl; D T Witiak; V V Hamparian; J H Hughes
Journal:  Antimicrob Agents Chemother       Date:  1980-08       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.